A rare case of pyopneumothorax

Areias, Vanda; Romero, Jose; Ruivo, Isabel; Brito, Ulisses
November 2010
Jornal Brasileiro de Pneumologia;nov2010, Vol. 36 Issue 6, p824
Academic Journal
No abstract available.


Related Articles

  • Clinical Relevance of Bacteriostatic versus Bactericidal Activity in the Treatment of Gram-Positive Bacterial Infections. Rhee, Kyn Y.; Gardiner, David F. // Clinical Infectious Diseases;9/1/2004, Vol. 39 Issue 5, p755 

    Presents a letter to the editor about clinical relevance of bacteriostatic versus bactericidal activity in the treatment of gram-positive bacterial infections.

  • Autoinflammatory disorders and patients with isolated serosal involvement. Cantarini, Luca; Lucherini, Orso Maria; Cimaz, Rolando; Brizi, Maria Giuseppina; Galeazzi, Mauro // Rheumatology International;Jul2011, Vol. 31 Issue 7, p979 

    A letter to the editor is presented in response to the article "A rare cause of refractory ascites in a child: familial Mediterranean fever," by M. Cakir and colleagues that was published in a previous issue.

  • Anti-MRSA Cephems: An Update. Springer, Dane M. // Current Medicinal Chemistry - Anti-Infective Agents;Jul2002, Vol. 1 Issue 3, p269 

    A review of recent developments in the field of anti-MRSA cephems is presented. The R.W. Johnson / Microcide collaboration seems to be the most advanced effort to date, but many other companies are continuing their efforts to develop a cephalosporin for use against serious Gram-positive...

  • Synercid: A new antibiotic for gram-positive infections. Baddour, Larry M. // Formulary;Dec2000 Supplement 3, Vol. 35 Issue 12, pS16 

    Presents a roundtable discussion on the use of Synercid antibiotic for gram-positive infections. List of discussion participants; Views on the relevance of treating infections caused by gram-positive cocci; Information on the use of the phrase multiple drug resistance; Details on the drug...

  • Vancomycin vs teicoplanin in the treatment of Gram-positive infections: a pharmacoeconomic analysis in a Turkish University Hospital. Aylin Sancar; Selen Yegenoglu; Robin de Vries; Maarten Postma; Nimet Simsek; Petros Pechlivanoglou; Serhat Unal // Pharmacy World & Science;Dec2008, Vol. 30 Issue 6, p916 

    Abstract   Objective The aim of this study was to estimate and compare the costs of vancomycin and teicoplanin in the treatment of Gram-positive hospital infections in Turkey using a cost minimisation analysis. Setting Hacettepe University Hospital, Ankara, Turkey. Method The...

  • Infection control: Clostridium difficile. Nazarko, Linda // British Journal of Healthcare Assistants;Jan2015, Vol. 9 Issue 1, p20 

    Clostridium difficile is a gram-positive, spore-forming bacteria that produces toxins when infection occurs. Infection can cause diarrhoea or life-threatening colitis (Barbut et al, 2007). There has been an 85% reduction in hospital-acquired Clostridium difficile infections over the past eight...

  • Introduction. Remington, Jack S. // Clinical Infectious Diseases;9/1/2000 Supplement 3, Vol. 31, pS123 

    Introduces several articles related to the topics discussed at the 'Strategies for the Successful Treatment of Gram-Positive Bacterial Infections' symposium held in September 1999. Panel discussion on the clinical impact of serious gram-positive bacterial infections and strategies to...

  • Strategies for the Successful Treatment of Gram-Positive Bacterial Infection. Remington, Jack S. // Clinical Infectious Diseases;9/1/2000 Supplement 3, Vol. 31, pS150 

    Presents a partial transcription of the panel discussion of the studies presented at 'Strategies for the Successful Treatment of Gram-Positive Bacterial Infections' symposium held in September 1999. Participants in the panel discussion; Multidisciplinary approach to infection control and the...

  • The Discovery of Linezolid, the First Oxazolidinone Antibacterial Agent. Ford, C.W.; Zurenko, G.E.; Barbachyn, M.R. // Current Drug Targets - Infectious Disorders;Aug2001, Vol. 1 Issue 2, p181 

    The emergence of new antibiotic-resistance in the significant Gram-positive pathogens in the last decade created a substantial medical need for new classes of antibacterial agents. Pharmacia Corporation scientists initiated a discovery research program in oxazolidinone chemistry and biology....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics